clinical trial · NCT07303907
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Definium Therapeutics US, Inc.·phase2·recruiting·n = 20
Autism Spectrum DisorderASDDT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
brief summary
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
started
Dec 3, 2025
primary completion
Aug 1, 2027
completion
Aug 1, 2027
last updated
Apr 6, 2026
detailed description
This study will enroll approximately twenty adults with Autism Spectrum Disorder (ASD) aged 18 to 65 years of age.
This is a single-center, open-label study to evaluate the effects after a single administration of DT402 to adults with ASD.
official title
An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol